Skip to main content
Sanofi India Ltd logo

Sanofi India Ltd — Investor Relations & Filings

Ticker · SANOFI ISIN · INE058A01010 LEI · 335800VFWLEY5V6PYH80 BSE.NS Manufacturing
Open in API
Filings indexed 1,554 across all filing types
Latest filing 2022-07-26 Notice of Dividend Amou…
Country IN India
Listing BSE.NS SANOFI

About Sanofi India Ltd

https://www.sanofi.in

Sanofi India Ltd focuses on the development, manufacturing, and marketing of a wide range of pharmaceutical products and healthcare solutions. The company operates across several therapeutic areas, including diabetes, cardiology, thrombosis, central nervous system disorders, and consumer healthcare. Its product portfolio includes established brands such as Lantus, Allegra, Combiflam, Amaryl, Avil, and Enterogermina. The organization prioritizes chronic disease management and acute care through a combination of prescription medicines and over-the-counter treatments. By integrating global research capabilities with local manufacturing excellence, the company provides specialized medical solutions aimed at improving patient health outcomes and addressing unmet medical needs.

Recent filings

Filing Released Lang Actions
Dear Sirs, The Board of Directors of the Company at its Meeting held today has declared One-Time Special Interim Dividend of Rs. 193 per equity share of Rs. 10 each for the financial year ....
Notice of Dividend Amount Classification · 100% confidence The document is a letter from the company secretary to stock exchanges announcing a One-Time Special Interim Dividend for the financial year ending 31st December 2022. It specifies the dividend amount, record date, and payment date. The content is an official announcement of dividend payment details rather than a full report or financial statement. The document length is short (1493 characters) and focuses solely on dividend declaration information. Therefore, it fits the category of Notice of Dividend Amount (DIV).
2022-07-26 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Unaudited Financial Results for the Quarter and Half Year ended 30th June 2022' and includes detailed financial statements such as the Statement of Unaudited Financial Results, Statement of Assets and Liabilities, and Statement of Cash Flows for the half year ended June 30, 2022. It also contains a Limited Review Report by the auditors, which is typical for interim or quarterly financial reports. The document references Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs quarterly financial disclosures in India. The presence of actual financial data and analysis for a period shorter than a full fiscal year confirms this is an Interim / Quarterly Report. The document length (15,000 characters) and content confirm it is the report itself, not just an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2022
2022-07-26 English
We refer to our letter dated 6th July 2022 informing you of our Board Meeting that was scheduled today. The Meeting of Board of Directors commenced at 02.00 p.m. and concluded at 5.10 p.m. ....
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Unaudited Financial Results for the Quarter and Half Year ended 30th June 2022' and includes detailed financial statements such as the Statement of Unaudited Financial Results, Statement of Assets and Liabilities, and Statement of Cash Flows for the half year ended June 30, 2022. It also contains a Limited Review Report by the auditors, which is typical for interim or quarterly financial reports. The document references Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs quarterly and half-yearly financial disclosures in India. The presence of actual financial data and analysis confirms this is a substantive financial report for a period shorter than a full fiscal year. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-07-26 English
General updates
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, for the quarter ended 31st March 2022. It is provided by the Registrar and Share Transfer Agent (RTA) and submitted to stock exchanges. The document is short (1421 characters) and is a certification letter rather than a full financial report. It does not contain financial statements or substantive financial data. According to the Certification Rule, such officer certifications or attestations should be classified as Regulatory Filings (RNS).
2022-07-21 English
General updates
Notice of Dividend Amount Classification · 95% confidence The document is a communication from Sanofi India Limited regarding the deduction of tax at source (TDS) on dividend payments. It details the tax deduction rules applicable to resident and non-resident shareholders, the documentation required to claim exemptions or treaty benefits, and instructions for shareholders to submit relevant forms. The document references a forthcoming dividend declaration and payment dates but does not itself declare dividends or provide financial statements. It is a shareholder communication about tax withholding on dividends rather than a financial report, earnings release, or regulatory filing of financial results. The content is focused on dividend tax deduction procedures and shareholder instructions, which aligns with a Notice of Dividend Amount filing. The document is over 10,000 characters, so it is not a brief announcement or a report publication announcement. Therefore, the most appropriate classification is Notice of Dividend Amount (DIV).
2022-07-21 English
Dear Sirs Please find enclosed copy of the letter on the above subject sent to the shareholders on 21st July 2022 through email who have registered their email ID with the Company / ....
Notice of Dividend Amount Classification · 95% confidence The document is a communication from Sanofi India Limited regarding the deduction of tax at source (TDS) on dividend payments. It details the tax deduction rules applicable to resident and non-resident shareholders, the documentation required to claim exemptions or treaty benefits, and instructions for shareholders to submit relevant forms. The document references a forthcoming dividend declaration and payment dates but does not itself declare dividends or provide financial statements. It is a detailed shareholder communication about tax withholding on dividends rather than a financial report or earnings release. It is not an announcement of voting results, board changes, or a regulatory filing of financial data. The content aligns with a Notice of Dividend Amount (DIV) as it informs shareholders about dividend payment and tax deduction details related to that dividend. The document length is over 10,000 characters, indicating it is a full communication rather than a brief announcement or report publication notice.
2022-07-21 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.